Novartis AG beats Q2 2025 expectations, but patent expiries and policy risks loom. Click for my updated look at NVS earnings ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations.

M Company (MMM) reports better-than-expected Q2 2025 results, raises full-year guidance, driven by growth in all business ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

Strength, Questions and 2025 Outlook ...

American Express stock has been stable but unspectacular this year, staying in lockstep with the broader market. With ...

Morgan Stanley (NYSE:MS) has seen a notable shift in its stock ownership as Massachusetts Financial Services Co. MA reduced ...